Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

bullseyecatnip 61 posts  |  Last Activity: 5 hours ago Member since: May 8, 2015
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    I wish Someone would have a real answer:

    by deanjm35 Jul 29, 2015 4:04 PM
    bullseyecatnip bullseyecatnip 5 hours ago Flag

    Enjoy your optimism. Unless there's new official news from the company, I plan to take break from reading this board until late Sept/Oct when I hope we get more official good news on EU. Didn't expect we'd ever see 7s-8s again, but no plans to sell... only add.

  • Reply to

    Under a dollar a share again....

    by f0rbes13 21 hours ago
    bullseyecatnip bullseyecatnip 6 hours ago Flag

    Last CEO spoke they were about 90% Nat Gas 10%

  • Contrary to stereotypes tossed about in anger on this board... a wide variety of people like their products and services and shop at a variety of stores - one being Whole Foods.

  • bullseyecatnip by bullseyecatnip Jul 30, 2015 7:10 AM Flag

    Upcoming PAX and Twitch Trade Shows Aug-Sept. And Star Wars game. And new Streaming deal with Comcast. And holiday buying seasons through YE15... to name a few, will drive sales ahead

    Sentiment: Buy

  • Reply to

    They did not miss by much, bottom line

    by gordon939 Jul 29, 2015 6:36 PM
    bullseyecatnip bullseyecatnip Jul 29, 2015 6:50 PM Flag

    Seriously, who would want them now and at today's price. BTW, I'm not short and I'll be underwater on all my shares.

  • Reply to

    They did not miss by much, bottom line

    by gordon939 Jul 29, 2015 6:36 PM
    bullseyecatnip bullseyecatnip Jul 29, 2015 6:41 PM Flag

    Wishful thinking (take over). Nothing would make me happier, but I won't be holding my breath.

  • bullseyecatnip bullseyecatnip Jul 29, 2015 6:23 PM Flag

    NO ONE PREDICTED $40-50 oil. NO ONE. And if $30 and God forbid $30 did come it would only be for a very short time and would likely signal something much more seriously wrong with the world. With all the unrest worldwide its more likely oil could be get back to 55-70 during winter 2015 -YE16.
    WLL is one of the least risky companies of this kind an size in the space.
    BUT you know all this. or maybe not... either way just a short rumor- and fear-monger.

  • bullseyecatnip bullseyecatnip Jul 29, 2015 1:50 PM Flag

    I don't see how he said implied he is smarter than Apples execs ... he just politely shared his though is all.

  • bullseyecatnip bullseyecatnip Jul 29, 2015 12:46 PM Flag

    BIG Pharma competitors can easily use tentacles to reach funding sources to hold new small competitors back... and I'm not saying this is wide spread, just that it can and does happen at times.

  • bullseyecatnip by bullseyecatnip Jul 29, 2015 9:21 AM Flag

    I question how this company makes money... and suspect of real world results and not also getting screwed by electric company... do the damage roofs and hold up under heavy snow?

  • Anyone who listened to this Q2 call should have increased confidence in their management, products and prospects for the future. Despite current and unrest problems with China, Russia, EU and Middle-east... they have tremendous potential in ALL of these regions that can be realized over time. North America is booming for them and show tremendous potential for a years to come. Haven't sold a share and may add on dips. Hoping they pick up much needed analyst coverage... those on the call asked good questions and are supporters of the Q and future.

  • bullseyecatnip bullseyecatnip Jul 28, 2015 9:32 AM Flag

    There could be worse acquisitions that's for sure! You suggest an excellent candidate that owns lots of content that Apple could desperately use and needs, especially if they roll out Apple TV someday. Another is Micron... would give them more direct control or price and manufacturing capabilities components inside their phones, computers, etc... and helps them better compete against Samsung.

  • Reply to

    this dive is

    by realfoxiegirl Jul 27, 2015 11:12 AM
    bullseyecatnip bullseyecatnip Jul 27, 2015 3:37 PM Flag

    MHR is 90% NatGas and only 10% oil.

  • Reply to

    Buyout coming Monday

    by maplecherypie May 4, 2015 3:22 PM
    bullseyecatnip bullseyecatnip Jul 27, 2015 1:46 PM Flag

    Better off buying Apple, GILD, MU at much safer valuations. Told you several years ago to get out of this.

  • Reply to

    Is anyone out there?

    by tke458 Jul 24, 2015 10:14 AM
    bullseyecatnip bullseyecatnip Jul 27, 2015 1:44 PM Flag

    No.... Buy Apple, GILD, MU

  • Reply to

    Hillary Clinton's Proposed New Capital Gains Tax

    by dopey3 Jul 24, 2015 10:18 AM
    bullseyecatnip bullseyecatnip Jul 26, 2015 6:52 AM Flag

    Rumors she will withdraw from the race between fall and spring using health concerns as a a reason.

  • bullseyecatnip by bullseyecatnip Jul 24, 2015 2:28 PM Flag

    Full disclosure, I did not think we would ever see the $7-8s again... after approval, so many reasons factual reasons that patients, prescribers, and insurers could all benefit in many ways. So no sense posting for a few months. Putting my shares in the sock draw... I'll open in when we are in the teens and rejoice when we are somedat at new highs - BO or no BO. - Best to longs.

  • bullseyecatnip bullseyecatnip Jul 24, 2015 7:49 AM Flag

    While often there is a devil is in the details, in this case however, NO devil... rather its ALL GOOD PROGRESS... standard operating procedure for any drug with EC/EU... looking forward to and hopeful for additional partnership news on or nearer official approval date.

    BIG sigh of relief. Ahhhhhhh....

    Sentiment: Buy

  • Reply to

    Press Release KERX

    by bullseyecatnip Jul 24, 2015 7:12 AM
    bullseyecatnip bullseyecatnip Jul 24, 2015 7:15 AM Flag

    "Keryx Receives CHMP Positive Opinion for Fexeric(R) (Ferric Citrate Coordination Complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease
    -Fexeric, if Approved, Will be the Only Absorbable, Iron-Based Phosphate Binder to Treat Elevated Serum Phosphorus Levels in Both Non-Dialysis and Dialysis CKD Patients in Europe-'

  • bullseyecatnip by bullseyecatnip Jul 24, 2015 7:12 AM Flag

    BOSTON, July 24, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (KERX) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ferric citrate coordination complex (EU approved brand name Fexeric(R)) recommending approval for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease (CKD). Fexeric was approved under the brand name Auryxia(TM) by the U.S. Food and Drug Administration in September 2014, and is indicated in the U.S. for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

    "We are pleased to receive this positive opinion from the CHMP for Fexeric, as it is an important step in providing a new treatment option in phosphorus management for adult patients with CKD in both the non-dialysis and dialysis settings," said John Neylan, M.D., chief medical officer of Keryx. "We look forward to the European Commission's decision in the coming months."

    The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union (EU) and Iceland, Norway and Liechtenstein. The EC generally follows the recommendation of the CHMP and typically issues its final opinion approximately two to three months following CHMP opinion. Keryx expects to make a decision about its EU commercial strategy by the end of 2015.

    DATA SUPPORTING POSITIVE OPINION

    The CHMP opinion is based on evidence from approximately 1900 patients, including two key clinical trials: a Phase 2, non-dialysis study and a 58-week, Phase 3 registration trial. In the Phase 3 trial, ferric citrate effectively reduced serum phosphorus levels to well within the KDOQI guidelines range of 3.5 mg/dL to 5.5 mg/dL. These data were published in 2014 in the Journal of the American Society of Nephrology.

    The most commonly reported adverse events during treatment were discolored feces (18%) and diarrhea (13%). All serious adverse reactions were gastrointestinal in nature (abdominal pain, constipation, diarrhea, gastritis, gastritis erosive, and hematemesis). The most commonly reported adverse reactions in CKD non-dialysis patients during treatment were discolored feces (27%) constipation (13%) and diarrhea (11%). A summary of the CHMP opinion can be accessed at ema.europa.eu.

    ABOUT HYPERPHOSPHATEMIA

    Managing patients on dialysis is complex as many metabolic factors, such as iron and phosphorus, are out of balance. Phosphate retention and resulting hyperphosphatemia in dialysis patients are typically associated with increased risk for heart and bone disease, and death. The majority of dialysis patients require chronic treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. In addition, iron can be severely depleted in dialyzed patients, who are often treated with intravenous iron and/or anemia medications, such as erythropoiesis stimulating agents (ESAs), to help boost red blood cell production.

    Related Quotes
    KERX
    9.26
    -2.94%
    Keryx Biopharmaceuticals Inc. Watchlist
    9.26-0.28(2.94%)
    NASDAQThu, Jul 23, 2015 4:00 PM EDT

    Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock TheStreet q 16 days ago
    Edited Transcript of KERX presentation 24-Jun-15 6:30pm GMT Thomson Reuters StreetEvents 24 days ago
    More
    IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA (ferric citrate)

    In the European Union, ferric citrate coordination complex is an investigational medicine and its safety, efficacy and product labeling have not been established. Keryx markets ferric citrate in the U.S. under the trade name Auryxia(TM).

    Contraindication: Patients with iron overload syndrome, e.g. hemochromatosis, should not take Auryxia (ferric citrate).

    Iron Overload: Iron absorption from Auryxia may lead to increased iron in storage sites. Iron parameters should be monitored prior to and while on Auryxia. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.

    Accidental Overdose of Iron: Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep Auryxia away from children as it contains iron. Call a poison control center or your physician in case of an accidental overdose in a child.

    Patients with Gastrointestinal Bleeding or Inflammation: Safety has not been established for these patients.

    Adverse Events: The most common adverse events with Auryxia were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%). Auryxia contains iron and may cause dark stools, which is considered normal with oral medications containing iron.

    Drug Interactions: Doxycycline should be taken at least 1 hour before Auryxia.

    For Full Prescribing Information for Auryxia in the U.S., please visit http://keryx.com/wp-content/uploads/Auryxia_PI_Keryx_112014.pdf.

    ABOUT KERYX BIOPHARMACEUTICALS, INC.

    Keryx Biopharmaceuticals, with offices in New York and Boston, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the Company launched its first FDA-approved product, Auryxia (ferric citrate) for the treatment of elevated serum phosphorus levels in patients with chronic kidney disease on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona(R) by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more information about Keryx, please visit www.keryx.com.

    CAUTIONARY STATEMENTS

    Some of the statements included in this press release, particularly those regarding the approval and subsequent commercialization of Fexeric, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: whether the European Commission will concur with the recommendation of the CHMP and grant approval of Fexeric; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

    Contact:
    KERYX BIOPHARMACEUTICALS CONTACTS:
    Amy Sullivan
    Vice President, Corporate Development and Public Affairs
    T: 617.466.3447
    amy.sullivan@keryx.com
    Lora Pike
    Senior Director, Investor Relations
    T: 617.466.3511
    lora.pike@keryx.com
    Rates

     View Comments (0)
    Share this

    
    Recommended for You
    Cisco CEO Robbins Cleans House; Price Tag for Set-Top Is Shockingly Low
    Newly installed Cisco Systems (CSCO) CEO Chuck Robbins is cleaning house, announcing this morning the company is selling the set-top box business to Technicolor for $600 million. Cisco, you’ll recall, acquired Scientific-Atlanta, one of the two dominant set-top providers at the time, for $7.1…
    Barrons.com
    CSCO $28.01 1.74%
    More like thisRemove
    Macy's 8pc Comforter Sets, All Sizes $40
    Macy's 8pc Bed Sets originally $100, are now just $40. All sizes and multiple styles available.
    Brad's DealsSponsored
    Here’s your golden opportunity to buy Apple’s stock
    The company’s results were astonishing, supporting a much higher share price, says Phil van Doorn.
    MarketWatch
    AAPL $125.16 -0.05%
    More like thisRemove
    Weatherford ups job cuts amid second quarter loss
    Weatherford International PLC (WFT) has increased its targeted number of job cuts for 2015 again. In the company's second-quarter earnings report released on July 22, Weatherford announced that it will boost cuts from 10,000 to 11,000 employees. The Ireland-domiciled services company, which…
    American City Business Journals
    WFT $11.10 3.93%
    More like thisRemove
    Play Video
    Singapore's Tourism Woes: Why Isn't Anyone Going?
    July 23 -- Bloomberg's Scarlet reports on Singapore's tourism worries. She speaks on "Bloomberg Markets."
    Bloomberg Video
    More like thisRemove

    How Apple and Samsung just caused this $104 billion company to cut 15% of its workforce
    The biggest news coming out of Qualcomm’s earnings report on Wednesday was its plan to...
    Business Insider
    QCOM $61.78 -3.75%
    More like thisRemove
    Get out of the past. Get FiOS.
    Pay for what you want and not for what you don’t. FiOS TV, Internet & Phone: $79.99/mo for 2 yrs + taxes, equip. charges, FDV & other fees w/ 2-yr agm
    Verizon FiOSSponsored
    Freeport-McMoRan (FCX) Stock Tumbling on Earnings Results
    Freeport-McMoRan (FCX) stock is falling on Thursday after the mining and energy company reported weak fiscal 2015 second quarter earnings results.
    TheStreet.com
    More like thisRemove
    Newmont Mining (NEM) Earnings Report: Q2 2015 Conference Call Transcript
    The following Newmont Mining (NEM) conference call took place on July 23, 2015, 10:00 AM ET. This is a transcript of that earnings call:
    TheStreet.com46 mins ago
    DB $33.83 1.20%
    More like thisRemove
    The Zacks Analyst Blog Highlights: Schlumberger, Halliburton, WPX Energy, Kinder Morgan and Energy Transfer Partners - Press Releases
    The Zacks Analyst Blog Highlights: Schlumberger, Halliburton, WPX Energy, Kinder Morgan and Energy Transfer Partners
    Zacks
    HAL $42.33 1.90%
    More like thisRemove
    Norfolk Southern's Stock Should Get Back on the Right Track
    Now is the time to buy the shares, before a rebound in the business is priced into the stock.
    TheStreet.com56 mins ago
    More like thisRemove
    Who is the richest person in your state? Find out!
    The countdown of the richest person in every state. There are few surprises here. Find out how your state compares.
    PlaymemberSponsored
    Cisco's new CEO just fixed John Chambers' most expensive mistake
    Two days before officially assuming the corner office, Chuck Robbins sold Cisco's TV set-top...
    Business Insider
    More like thisRemove
    Tsinghua Holdings chief says still in Micron talks, hopeful on deal
    China's Tsinghua Holdings is still discussing a potential deal to buy U.S. chipmaker Micron Technology Inc (MU.O) and hopes it could eventually go through, the state-backed investment company's chairman told Reuters on Thursday. Sources told Reuters earlier this week that Micron has dismissed an…
    Reuters
    More like thisRemove
    Juniper Vaults 11% Higher: Q2 Rev, EPS Beat, Q3 View Beats
    Networker Juniper Networks (JNPR) this afternoon reported Q2 revenue and profit that topped analysts' expectations, sending its shares higher in late trading. Juniper said its operating profit margin rose to 25.2%, on a non-GAAP basis, up 6.7 points from the prior-year period. CEO Rami Rahim said…
    Barrons.com
    JNPR $26.49 1.15%
    More like thisRemove
    Amerisourcebergen (ABC) Earnings Report: Q3 2015 Conference Call Transcript
    The following Amerisourcebergen (ABC) conference call took place on July 23, 2015, 11:00 AM ET. This is a transcript of that earnings call:
    TheStreet.com28 mins ago
    CS $29.69 5.73%
    More like thisRemove
    Think Gold Is "Safe"? Think Again.
    You've probably been told time and again that gold is the best way to protect your hard-earned money. But is there another side to this story?
    The Motley FoolSponsored
    United Continental Holdings (UAL) Earnings Report: Q2 2015 Conference Call Transcript
    The following United Continental Holdings (UAL) conference call took place on July 23, 2015, 10:30 AM ET. This is a transcript of that earnings call:
    TheStreet.com
    UAL $56.67 -0.70%
    More like thisRemove
    Play
    What One Question Reporters Need to Ask Donald Trump
    July 22 -- Former House Leader Deputy Chief of Staff Doug Heye weighs in on the surge in Donald Trump's presidential bid poll numbers. Heye speaks on "Bloomberg Markets."
    Bloomberg Video
    More like thisRemove
    Here's what's in Donald Trump's stock portfolio
    Donald Trump's personal financial disclosure report, which was filed as part of his...
    Business Insider
    More like thisRemove
    Qualcomm's potential break-up could lead to courtship with Intel
    Wall Street says Intel Corp is the best suitor for Qualcomm Inc's chip unit, if the maker of Snapdragon mobile processors decides to break itself up. "The chip deal to end all chip deals," says Cowen and Co analyst Timothy Arcuri, would give Intel's smartphone chip making business a much-needed…
    Reuters
    More like thisRemove
    Get Instant Online Access To Your Credit Report
    It's completely free to get your Experian® Credit Report. No credit card required. Get yours today at freecreditreport.com
    freecreditreport.comSponsored
    Cliffs Natural Resources Hits 12-year Low
    Shares of Cliffs Natural Resources (CLF) have plunged to a 12-year low today, after BHP Billiton (BHP) said that iron-ore production would increase during its fiscal 2016--just what the market for iron ...
    Barrons.com
    More like thisRemove
    Cypress Semiconductor (CY) Stock Gains on Earnings Beat
    Cypress Semiconductor (CY) shares are higher Thursday after the chipmaker beat analysts' estimates for earnings in the second quarter.
    TheStreet.com
    More like thisRemove
    Bank of America: Why CFO Departure is a Big Deal
    Shares of Bank of America (BAC) are leading bank stocks lower today after the big bank's CFO unexpectedly left the company. JPMorgan's Vivek Juneja and team explain why that's a big deal: Bank of America’s well regarded CFO, Bruce Thompson, is leaving – a surprise announcement. Bruce Thompson has…
    Barrons.com
    More like thisRemove
    Load more stories
    Press Releases

    Faruqi & Faruqi, LLP is Investigating Keryx Biopharmaceuticals, Inc. (KERX) on Behalf of its Shareholders
    Keryx Announces Two National Insurance Providers Added Auryxia(TM) to Their Medicare Part D Formularies
    Keryx Biopharmaceuticals to Present at the JMP Securities Life Sciences Conference 2015
    More Press Release for Keryx Biopharmaceuticals Inc.
    What to read next

    Big-name investors stand atop a welcome 'wall of worry'

    When it comes to Summer, Florida does it right.
    Sponsored VISIT FLORIDA 

    Commodities slump: Is there trouble ahead for the global economy?

    The tide is turning against rich CEOs

    'Serious correction' ahead to delay Fed rate hike: Portfolio manager

    Why Aren’t Homeowners Taking Advantage of HARP?
    Sponsored LowerMyBills 

    How Snapchat and Facebook could win the 2016 election

    Man rents out back of van on Airbnb for $99/night

    Why Has Oil Entered Bear Territory?

    How To Get Better Knees - Do This Daily
    Sponsored Instaflex Advanced 
    Anthem to buy Cigna in $54.2B deal
    Advertising's digital challenge: Sir Martin Sorrell
    Amazon Shares Surge Following Profit Delivery

    New “Dollar Substitute” coming as early as October
    Sponsored Stansberry Research 
    It's official... Anthem to buy Cigna
    China Has Entered the Bust Phase: Whelan
    Anthem to buy Cigna in health insurance mega-deal

    Repair Damaged Lung Tissue with Stem Cell Therapy
    Sponsored Lung Institute 
    US stocks set for rebound as Amazon shares surge

    The Best Way To See Your Credit Report For Free
    Sponsored freecreditreport.com 
    Anthem to buy Cigna for $48.4 billion after year of talks
    China manufacturing slumps to 15-month low
    Could Twitter stop the next terrorist attack?

    Macy's 8pc Comforter Sets, All Sizes $40
    Sponsored Brad's Deals 
    Health insurer Anthem to buy Cigna in $54.2 billion deal
    Metals hit multi-year lows on global growth concerns, dollar rises

    Copyright © 2015 GlobeNewswire . All rights reserved. Redistribution of this content is expressly prohibited without prior written consent. GlobeNewswire makes no claims concerning the accuracy or validity of the information, and shall not be held liable for any errors, delays, omissions or use thereof.
    Data Disclaimer
    Help / Suggestions Privacy About Our Ads Terms

SNTA
2.16+0.06(+2.86%)12:32 PMEDT